Secukinumab in psoriasis

Relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials

Gottlieb, A., Strober, B., Lebwohl, M., Kaufmann, R., Pariser, D., Narbutas, R., Nyirady, J., Zhao, Y., Tran, MH., McLeod, L., Odom, D., & Elewski, B. (2015). Secukinumab in psoriasis: Relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials. Journal of the American Academy of Dermatology, 72(5, Suppl. 1), AB250. https://doi.org/10.1016/j.jaad.2015.02.997

Abstract

Background: Secukinumab, a fully human antiinterleukin 17A monoclonal antibody, was evaluated in ERASURE and FIXTURE, two phase 3 multicenter double blind vs placebo clinical studies, for efficacy and safety in subjects with moderate to severe plaque psoriasis. Data from these trials provided an opportunity to evaluate the relationship between traditional clinical outcomes and patient-reported symptoms.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

The daily association between affect and alcohol use: A meta-analysis of individual participant data
Article

Protection of forest ecosystems in the eastern United States from elevated atmospheric deposition of sulfur and nitrogen
Article

The use of patient experience feedback in rehabilitation quality improvement and codesign activities
Article

SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia